Published in J Clin Oncol on October 15, 2002
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones (2005) 5.22
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood (2009) 1.61
Diversity and recognition efficiency of T cell responses to cancer. PLoS Med (2004) 1.36
A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J Immunol (2009) 1.28
Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol (2011) 1.24
Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res (2009) 1.17
Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines (2010) 1.15
Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Rev Vaccines (2011) 1.11
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs (2009) 1.09
Personalized dendritic cell-based tumor immunotherapy. Immunotherapy (2010) 1.08
Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics (2008) 1.03
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother (2012) 1.02
Biomarkers for rheumatoid arthritis: making it personal. Scand J Clin Lab Invest Suppl (2010) 1.00
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci (2007) 0.97
Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro Oncol (2005) 0.97
Immunotherapy of distant metastatic disease. Ann Oncol (2009) 0.96
T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. J Transl Med (2005) 0.92
Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurg Clin N Am (2010) 0.91
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer (2004) 0.91
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89
Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med (2004) 0.86
Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin Exp Immunol (2007) 0.86
Molecular chaperones and heat shock proteins in atherosclerosis. Am J Physiol Heart Circ Physiol (2011) 0.84
Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine. J Clin Immunol (2005) 0.84
A novel method to identify and characterise peptide mimotopes of heat shock protein 70-associated antigens. J Immune Based Ther Vaccines (2006) 0.84
Understanding the response to immunotherapy in humans. Springer Semin Immunopathol (2005) 0.83
The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines. BMC Cancer (2008) 0.83
Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med (2010) 0.82
Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol (2010) 0.82
Heat shock protein vaccines against glioblastoma: from bench to bedside. J Neurooncol (2015) 0.82
Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy (2013) 0.81
High molecular weight stress proteins: Identification, cloning and utilisation in cancer immunotherapy. Int J Hyperthermia (2013) 0.81
Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies. J Transl Med (2011) 0.80
Unfolding the Role of Large Heat Shock Proteins: New Insights and Therapeutic Implications. Front Immunol (2016) 0.80
Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci U S A (2004) 0.80
Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of Cancer. Front Immunol (2016) 0.80
Calreticulin requires an ancillary adjuvant for the induction of efficient cytotoxic T cell responses. Mol Immunol (2007) 0.79
Preparation of a heat-shock protein 70-based vaccine from DC-tumor fusion cells. Methods Mol Biol (2011) 0.78
Identification of peptide mimotopes of gp96 using single-chain antibody library. Cell Stress Chaperones (2010) 0.78
Fusion proteins of Hsp70 with tumor-associated antigen acting as a potent tumor vaccine and the C-terminal peptide-binding domain of Hsp70 being essential in inducing antigen-independent anti-tumor response in vivo. Cell Stress Chaperones (2006) 0.78
A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients. Cell Stress Chaperones (2007) 0.78
A tale of two pities: autologous melanoma vaccines on the brink. Hum Vaccin Immunother (2012) 0.78
Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system. Int J Mol Sci (2015) 0.78
A role for the heat shock protein-CD91 axis in the initiation of immune responses to tumors. Immunol Res (2011) 0.77
Vaccinating patients with autologous tumor. J Clin Oncol (2002) 0.77
Salmonella typhimurium stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model. Clin Exp Immunol (2007) 0.77
Prophylactic Antitumor Effect of Mixed Heat Shock Proteins/Peptides in Mouse Sarcoma. Chin Med J (Engl) (2015) 0.76
Glycoprotein 96-mediated presentation of human immunodeficiency virus type 1 (HIV-1)-specific human leukocyte antigen class I-restricted peptide and humoral immune responses to HIV-1 p24. Clin Vaccine Immunol (2009) 0.76
Experimental study on therapeutic effect of in vivo expression of Cell I-Hep II recombinant polypeptide of fibronectin on murine H22 hepatocellular carcinoma. World J Gastroenterol (2003) 0.76
Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies. Med Oncol (2012) 0.76
Biology of human cutaneous melanoma. Cancers (Basel) (2010) 0.75
The war on cancer: a report from the front lines. Proc (Bayl Univ Med Cent) (2006) 0.75
Tumor Vaccines for Malignant Gliomas. Neurotherapeutics (2017) 0.75
Advances in immunotherapy for melanoma management. Hum Vaccin Immunother (2016) 0.75
Targeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency. World J Gastroenterol (2007) 0.75
Immunotherapy in non-renal carcinomas. Urologe A (2004) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58
Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med (2002) 12.83
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell (2008) 4.47
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15
Abi1 is essential for the formation and activation of a WAVE2 signalling complex. Nat Cell Biol (2004) 4.04
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Sra-1 and Nap1 link Rac to actin assembly driving lamellipodia formation. EMBO J (2004) 3.31
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2013) 3.28
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One (2009) 3.10
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 3.02
Novel roles of formin mDia2 in lamellipodia and filopodia formation in motile cells. PLoS Biol (2007) 3.01
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev (2006) 2.87
Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res (2007) 2.80
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res (2006) 2.77
Protein complexes regulating Arp2/3-mediated actin assembly. Curr Opin Cell Biol (2005) 2.63
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol (2011) 2.62
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res (2006) 2.61
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 2.54
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol (2009) 2.48
Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg (2002) 2.47
Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer (2008) 2.45
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One (2009) 2.43
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Eps8 controls actin-based motility by capping the barbed ends of actin filaments. Nat Cell Biol (2004) 2.40
Rab5 is a signalling GTPase involved in actin remodelling by receptor tyrosine kinases. Nature (2004) 2.39
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology (2013) 2.30
Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg (2004) 2.20
Regulation of actin dynamics by WASP and WAVE family proteins. Trends Cell Biol (2004) 2.19
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2004) 2.16
Abi1 regulates the activity of N-WASP and WAVE in distinct actin-based processes. Nat Cell Biol (2005) 2.16
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol (2008) 2.10
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst (2005) 2.09
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Conventional hemangiopericytoma: modern analysis of outcome. Cancer (2002) 2.04
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst (2004) 2.02
IRSp53 links the enterohemorrhagic E. coli effectors Tir and EspFU for actin pedestal formation. Cell Host Microbe (2009) 2.01
Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res (2009) 2.00
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology (2005) 2.00
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol (2003) 1.94
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother (2011) 1.94
Increased ethanol resistance and consumption in Eps8 knockout mice correlates with altered actin dynamics. Cell (2006) 1.92
Regulation of cell shape by Cdc42 is mediated by the synergic actin-bundling activity of the Eps8-IRSp53 complex. Nat Cell Biol (2006) 1.92
Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J Cell Biol (2003) 1.91
Sentinel-node biopsy in melanoma. N Engl J Med (2006) 1.90
Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol (2002) 1.89
Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev (2012) 1.82
A novel actin barbed-end-capping activity in EPS-8 regulates apical morphogenesis in intestinal cells of Caenorhabditis elegans. Nat Cell Biol (2004) 1.82
A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol (2003) 1.81
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood (2005) 1.80